-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology: Breakthrough in Host Versus Graft (HVG) Research
Author:
InnoModels Biotechnology
Release time:
2024-01-12
InnoModels Biotechnology is committed to research and innovation in the life sciences and has recently made an impressive breakthrough in the field of host-versus-graft (HVG) response. This achievement will open up new possibilities in areas such as organ transplantation and immunotherapy, and is expected to solve problems such as transplant rejection.
What is host-versus-graft (HVG)?
Host-versus-graft reaction (HVG) is the rejection of allograft tissue or organ by the host organism. This reaction involves the activation of the immune system, leading to graft damage and rejection, and is one of the major challenges in the field of organ transplantation.
InnoModels's research results
The breakthroughs made by InnoModels Biotechnology in the field of HVG research mainly include the following aspects:
1. New strategies for immune regulation:
The company has developed a series of novel immunomodulatory strategies that can effectively slow down the host immune system's attack on grafts. These strategies are based on in-depth immunological research and provide new ideas for reducing graft rejection.
2. Precise immunosuppressive techniques:
Through the introduction of precise immunosuppressive techniques, InnoModels Biotechnology has successfully reduced host rejection of allogeneic grafts while maintaining the immune system's effective response to other pathogens, achieving precise regulation of immune balance.
3. Individualised treatment protocols:
Based on in-depth understanding of individual immune characteristics, the company proposes individualised treatment protocols to ensure more precise and effective regulation of each patient's graft response and minimise the risk of rejection.
4. Multidisciplinary research:
The research conducted by InnoModels Biotechnology involves multiple disciplines, including immunology, molecular biology, gene editing, and so on. This multidisciplinary research model provides a more comprehensive and in-depth perspective for HVG research.

Application Prospects and Significance
The results achieved by InnoModels Biotechnology in HVG research have brought new hope to the field of organ transplantation. It is not only expected to reduce the risk of organ transplant rejection, but also provides a theoretical and practical basis for the development of safer and more effective immunotherapy methods. This is of far-reaching significance in promoting the development of the medical field and improving the success rate of organ transplantation.
Overall, the results of InnoModels's research in the field of host-versus-graft (HVG) response are expected to provide innovative solutions to the immune problems in organ transplantation. If you have any specific questions or need more in-depth information about InnoModels Biologics' host-versus-graft (HVG) response, please feel free to contact us.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd